UNIGE document Scientific Article
previous document  unige:74304  next document
add to browser collection

Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors

Batlle, J
Lopez, M F
Brackmann, H H
Gaillard, S
Goudemand, J
Maass, E
show hidden authors show all authors [1 - 11]
Published in Haemophilia. 1999, vol. 5, no. 6, p. 431-5
Abstract We report on 11 patients (nine unrelated and a brother pair) with severe haemophilia A and factor VIII (FVIII) inhibitor, in whom immune tolerance (IIT) was induced with recombinant FVIII (r-FVIII). Their age ranged from 11 months to 47 years. The number of exposure days (ED) at inhibitor detection varied from 11 to 130. Nine of the 11 patients were high responders ¿>10 Bethesda units (BU) with peak inhibitor levels ranging from 10 to 566 BU. The other two were low responders with peak levels between 0.7 and 2 BU. Before inhibitor detection, the patients had been receiving products of various purities. The IIT regimens were very heterogeneous, and the treatment schedule varied from a short period with 50 IU kg-1 every 2 days, followed by 100 IU kg-1 every 2 days and then 220 IU kg-1 daily. The outcome was considered successful when the inhibitor level fell to 0.6 BU or lower after IIT treatment. The outcome overall was successful in nine out of 11 patients (81.8%), with the nine successful cases comprising seven of the nine high responders (77.8%) and the two low responders. Definite failure of IIT was observed in one high responder after two different IIT regimens. A second high responder is still on IIT treatment. All patients in whom IIT was successful are currently receiving r-FVIII on demand or prophylactically at various dosages. Despite the variability of the patient characteristics and the IIT schedules, this study demonstrates that r-FVIII represents an effective alternative for the eradication of inhibitors through IIT.
Keywords AdolescentAdultChildChild, PreschoolEuropeFactor VIII/administration & dosageHemophilia A/drug therapy/immunologyHumansImmune Tolerance/drug effectsInfantIsoantigens/blood/drug effectsMiddle AgedQuestionnairesRecombinant Proteins/administration & dosageTreatment Outcome
PMID: 10583531
Full text
Article (Published version) (59 Kb) - document accessible for UNIGE members only Limited access to UNIGE
(ISO format)
BATLLE, J et al. Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors. In: Haemophilia, 1999, vol. 5, n° 6, p. 431-5. https://archive-ouverte.unige.ch/unige:74304

163 hits

0 download


Deposited on : 2015-07-27

Export document
Format :
Citation style :